Ertapenem Antimicrobial Coverage
Ertapenem is a Group 1 carbapenem with broad-spectrum activity against gram-positive cocci (excluding MRSA and enterococci), gram-negative Enterobacteriaceae (including ESBL producers), and anaerobes—but critically lacks activity against Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant Staphylococcus aureus (MRSA), and Enterococcus species 1.
Gram-Negative Coverage
Ertapenem demonstrates excellent activity against Enterobacteriaceae:
- Escherichia coli (including ESBL producers)
- Klebsiella pneumoniae and other Klebsiella species (including ESBL producers)
- Proteus mirabilis
- Enterobacter cloacae (including AmpC producers)
- Haemophilus influenzae (beta-lactamase negative strains)
- Moraxella catarrhalis
The drug shows particularly potent activity against extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and AmpC-producing organisms 2. This makes it valuable for community-acquired infections where ESBL organisms are suspected 3.
Critical gap: Ertapenem has no clinically useful activity against Pseudomonas aeruginosa or Acinetobacter species 2, 1. This distinguishes it from Group 2 carbapenems (imipenem, meropenem, doripenem) and is the most important limitation when selecting empiric therapy.
Gram-Positive Coverage
Ertapenem covers:
- Staphylococcus aureus (methicillin-susceptible isolates only—MSSA)
- Streptococcus pneumoniae (penicillin-susceptible isolates)
- Streptococcus pyogenes (Group A Streptococcus)
- Streptococcus agalactiae (Group B Streptococcus)
Critical gaps: Ertapenem is not active against MRSA or Enterococcus species (including E. faecalis and E. faecium) 4, 1. Guidelines explicitly state that empiric enterococcal coverage is not necessary for community-acquired intra-abdominal infections, but if enterococcal coverage is required based on culture data or clinical severity, a separate agent (vancomycin, linezolid, or daptomycin) must be added 3.
Anaerobic Coverage
Ertapenem provides comprehensive anaerobic coverage 1:
- Bacteroides fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. uniformis)
- Clostridium species (including C. clostridioforme, C. perfringens)
- Peptostreptococcus species
- Porphyromonas asaccharolytica
- Prevotella bivia
- Eubacterium lentum
- Fusobacterium species
This broad anaerobic spectrum makes ertapenem suitable as monotherapy for polymicrobial infections involving bowel flora 4, 3.
Clinical Context and Appropriate Use
Ertapenem is recommended for moderate-to-severe community-acquired infections where ESBL organisms are suspected but Pseudomonas is unlikely 4, 3. Specific indications include:
- Complicated intra-abdominal infections (community-acquired, mild-to-moderate severity)
- Diabetic foot infections without osteomyelitis (moderate-to-severe)
- Community-acquired pneumonia
- Complicated urinary tract infections including pyelonephritis
- Acute pelvic infections
Do not use ertapenem when:
- Pseudomonas aeruginosa is suspected (healthcare-associated infections, severe sepsis with risk factors, neutropenic patients)
- MRSA coverage is needed
- Enterococcal coverage is required based on severity or prior cultures
- Late-onset nosocomial infections are being treated 5
Important Caveats
The 2010 IDSA/SIS guidelines express concern that broad use of ertapenem may accelerate emergence of carbapenem-resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter 3. Reserve ertapenem for situations where its specific spectrum is needed—avoid using it as a "default" broad-spectrum agent when narrower options are appropriate.
For severe infections or critically ill patients, consider that standard dosing (1g daily) may not achieve optimal pharmacodynamic targets; some data suggest more frequent dosing or continuous infusion may be needed in ICU patients 5.
When treating complicated intra-abdominal infections empirically, ertapenem provides adequate coverage for the typical polymicrobial flora without requiring combination therapy, unlike regimens using third-generation cephalosporins or fluoroquinolones (which require metronidazole for anaerobic coverage) 3, 6.